Research programme: anti-cancer antibodies - SymphogenAlternative Names: Sym 014
Latest Information Update: 19 Nov 2016
At a glance
- Originator Symphogen
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Leukaemia